Search research articles
Contact Us
Filters
Showing results (51-60 of 66) with videos related to
Page
of 7
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 26, 2026
Durvalumab Plus Paclitaxel, with or without Capivasertib or Oleclumab, in Patients with Locally Advanced/Metastatic Triple-Negative Breast Cancer
Peter Schmid, Cynthia X Ma, Yeon Hee Park, et al.
JAMA Oncology
|
November 17, 2022
Avelumab Plus Talazoparib in Patients With Advanced Solid Tumors: The JAVELIN PARP Medley Nonrandomized Controlled Trial
Timothy A Yap, Aditya Bardia, Michael Dvorkin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 11, 2017
A Novel Murine GITR Ligand Fusion Protein Induces Antitumor Activity as a Monotherapy That Is Further Enhanced in Combination with an OX40 Agonist
Rebecca Leyland, Amanda Watkins, Kathy A Mulgrew, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 22, 2023
Tumor Mutational Burden as a Predictor of Survival with Durvalumab and/or Tremelimumab Treatment in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Sophie Wildsmith, Weimin Li, Song Wu, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
September 7, 2024
Durvalumab With or Without Tremelimumab in Combination With Chemotherapy in First-Line Metastatic NSCLC: Five-Year Overall Survival Outcomes From the Phase 3 POSEIDON Trial
Solange Peters, Byoung Chul Cho, Alexander V Luft, et al.
Oncotarget
|
September 15, 2016
Phenotypic screening reveals TNFR2 as a promising target for cancer immunotherapy
Geoffrey S Williams, Bina Mistry, Sandrine Guillard, et al.
JAMA Oncology
|
November 17, 2022
Avelumab Plus Talazoparib in Patients With BRCA1/2- or ATM-Altered Advanced Solid Tumors: Results From JAVELIN BRCA/ATM, an Open-Label, Multicenter, Phase 2b, Tumor-Agnostic Trial
Alison M Schram, Nicoletta Colombo, Edward Arrowsmith, et al.
Biorxiv : the Preprint Server for Biology
|
February 6, 2026
An integrated, scaled approach to resolve TSC2 variants of uncertain significance
Carina G Biar, Ziyu R Wang, Nathan D Camp, et al.
Oncoimmunology
|
April 14, 2017
MEDI1873, a potent, stabilized hexameric agonist of human GITR with regulatory T-cell targeting potential
Natalie J Tigue, Lisa Bamber, John Andrews, et al.
Cancer Immunology Research
|
December 8, 2016
Rational Selection of Syngeneic Preclinical Tumor Models for Immunotherapeutic Drug Discovery
Suzanne I S Mosely, John E Prime, Richard C A Sainson, et al.
Page
of 7
Search research articles
Search
Showing results (51-60 of 66) with videos related to
Sort By:
Page
of 7
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 26, 2026
Durvalumab Plus Paclitaxel, with or without Capivasertib or Oleclumab, in Patients with Locally Advanced/Metastatic Triple-Negative Breast Cancer
Peter Schmid, Cynthia X Ma, Yeon Hee Park, et al.
JAMA Oncology
|
November 17, 2022
Avelumab Plus Talazoparib in Patients With Advanced Solid Tumors: The JAVELIN PARP Medley Nonrandomized Controlled Trial
Timothy A Yap, Aditya Bardia, Michael Dvorkin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 11, 2017
A Novel Murine GITR Ligand Fusion Protein Induces Antitumor Activity as a Monotherapy That Is Further Enhanced in Combination with an OX40 Agonist
Rebecca Leyland, Amanda Watkins, Kathy A Mulgrew, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 22, 2023
Tumor Mutational Burden as a Predictor of Survival with Durvalumab and/or Tremelimumab Treatment in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Sophie Wildsmith, Weimin Li, Song Wu, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
September 7, 2024
Durvalumab With or Without Tremelimumab in Combination With Chemotherapy in First-Line Metastatic NSCLC: Five-Year Overall Survival Outcomes From the Phase 3 POSEIDON Trial
Solange Peters, Byoung Chul Cho, Alexander V Luft, et al.
Oncotarget
|
September 15, 2016
Phenotypic screening reveals TNFR2 as a promising target for cancer immunotherapy
Geoffrey S Williams, Bina Mistry, Sandrine Guillard, et al.
JAMA Oncology
|
November 17, 2022
Avelumab Plus Talazoparib in Patients With BRCA1/2- or ATM-Altered Advanced Solid Tumors: Results From JAVELIN BRCA/ATM, an Open-Label, Multicenter, Phase 2b, Tumor-Agnostic Trial
Alison M Schram, Nicoletta Colombo, Edward Arrowsmith, et al.
Biorxiv : the Preprint Server for Biology
|
February 6, 2026
An integrated, scaled approach to resolve TSC2 variants of uncertain significance
Carina G Biar, Ziyu R Wang, Nathan D Camp, et al.
Oncoimmunology
|
April 14, 2017
MEDI1873, a potent, stabilized hexameric agonist of human GITR with regulatory T-cell targeting potential
Natalie J Tigue, Lisa Bamber, John Andrews, et al.
Cancer Immunology Research
|
December 8, 2016
Rational Selection of Syngeneic Preclinical Tumor Models for Immunotherapeutic Drug Discovery
Suzanne I S Mosely, John E Prime, Richard C A Sainson, et al.
Page
of 7